T1	p 25 43	prostatic cancer .
T2	p 153 216	Group in previously untreated patients with prostatic cancer in
T3	p 623 653	patients with advanced disease
T4	i 136 152	EORTC Urological
T5	i 243 317	Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate
T6	i 343 371	Stilboestrol versus Estracyt
T7	i 473 485	Stilboestrol
T8	i 716 751	either Adriamycin or Procarbazine .
T9	i 807 819	Procarbazine
T10	o 550 574	significant side effects
T11	o 752 776	Toxicity and early death